CorMedix Inc.
CRMD evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for CRMD—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CRMD
CorMedix Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for the prevention of catheter-related bloodstream infections, with its lead product DefenCath (taurolidine and heparin) approved and launched in the U.S. dialysis market.
Key risk: Commercial adoption dependence
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 3 clinical trials · 3 catalysts · 1 FDA decision for CorMedix Inc..
CorMedix Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for the prevention of catheter-related bloodstream infections, with its lead product DefenCath (taurolidine and heparin) approved and launched in the U.S. dialysis market.
- Reported total revenue of $101.9M and net income of $26.0M for the six months ended June 30, 2026 [sec].
- Cash and equivalents of $257.7M as of June 30, 2026, with shareholders' equity of $220.6M [sec].
- DefenCath is approved and commercialized in the U.S. under a Transitional Drug Add-on Payment Adjustment (TDAPA) program that provides five years of additional reimbursement beyond the ESRD bundled rate [sec_mda · as of 2024-05-09].
- The company has multi-year commercial supply agreements covering roughly 60% of U.S. outpatient dialysis centers [sec_mda · as of 2025-03-25].
- A Phase 3 topline readout is expected on January 1, 2028, and patent/exclusivity expiries for REZZAYO and DEFENCATH are scheduled for 2038 and 2042, respectively [upcoming catalysts].
What works
- DefenCath has secured broad commercial coverage with contracts representing about 60% of U.S. outpatient dialysis centers, providing a large addressable patient base [sec_mda · as of 2025-03-25].
- The TDAPA program offers five years of additional reimbursement beyond the standard ESRD bundled rate, supporting revenue growth during the early commercial phase [sec_mda · as of 2024-05-09].
- The company achieved profitability with net income of $26.0M in the first half of 2026, indicating improving operating leverage [sec].
- A strong cash position of $257.7M as of June 30, 2026 provides financial flexibility to fund operations and development activities [sec].
What to weigh
- Revenue and profitability remain dependent on successful continued adoption of DefenCath; failure to maintain or expand market penetration could reverse recent financial improvements [sec_mda · as of 2025-03-25].
- The company faces risks from reimbursement dynamics and the timing of product adoption, which could affect revenue predictability [sec_mda · as of 2026-08-13].
- Clinical development of pipeline candidates is subject to uncertainties in enrollment, costs, and timelines, with no guarantee of successful outcomes [sec_mda · as of 2026-03-05].
- Future capital needs may require dilutive equity or debt financing, as the company has an ATM program and shelf registration available for additional securities issuance [sec_mda · as of 2025-08-07].
From the filings
Quoted directly from source documents.
DefenCath has commercial supply agreements covering roughly 60% of U.S. outpatient dialysis centers.
“We believe the currently contracted customer base represents roughly 60% of the outpatient dialysis centers in the U.S.”
SEC MD&A · March 25, 2025
The TDAPA program provides five years of additional reimbursement for DefenCath.
“The TDAPA program currently provides for five years of additional payment reimbursement beyond the ESRD bundled rate to outpatient providers.”
SEC MD&A · May 9, 2024
Catalyst timeline
- 2028-01-01 · Phase3_Topline — Topline results from a Phase 3 adaptive study will provide key efficacy and safety data for a pipeline candidate.
- 2038-07-14 · Patent_Expiry · REZZAYO — Patent/exclusivity expiry for REZZAYO may open the product to generic competition.
- 2042-04-15 · Patent_Expiry · DEFENCATH — Patent/exclusivity expiry for DEFENCATH may open the product to generic competition.
Risks & what to watch (4)›
Key risks
- Commercial adoption dependence — Revenue growth relies on continued adoption of DefenCath; failure to maintain market penetration could reverse profitability [sec_mda · as of 2025-03-25].
- Reimbursement and pricing uncertainty — Changes in reimbursement dynamics or TDAPA program terms could materially affect revenue [sec_mda · as of 2026-08-13].
- Clinical development risks — Pipeline candidates face uncertainties in enrollment, costs, and outcomes; no guarantee of successful development [sec_mda · as of 2026-03-05].
- Potential dilutive financing — Future capital needs may require equity or debt issuance, diluting existing shareholders [sec_mda · as of 2025-08-07].
What to watch
- Continued commercial adoption of DefenCath and its impact on revenue growth and profitability [sec_mda · as of 2026-08-13].
- Phase 3 topline data readout expected on January 1, 2028, which could inform pipeline value [upcoming catalysts].
- Reimbursement dynamics under the TDAPA program and any changes to the ESRD bundled payment system [sec_mda · as of 2024-05-09].
- Capital allocation decisions, including potential use of the ATM program or shelf registration for additional funding [sec_mda · as of 2025-08-07].
Sources: SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run CorMedix Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available CorMedix Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
Profitable (positive operating cash flow)
D/E 0.96 · 18% dilution
Lead: Phase 3
2 candidates
3 upcoming, next in ~489d
No insider transactions in the last 180 days
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
189
Total value held
$307.7M
| Holder | Shares | Value |
|---|---|---|
| deep track capital, lp | 6,274,076 | $42.6M |
| vanguard capital management llc | 6,259,312 | $42.5M |
| blackrock, inc. | 5,967,575 | $40.5M |
| state street corp | 2,191,843 | $14.9M |
| susquehanna international group, llp | 1,894,810 | $12.9M |
| royce & associates lp | 1,887,532 | $12.8M |
| geode capital management, llc | 1,816,907 | $12.3M |
| oberweis asset management inc/ | 1,211,115 | $8.2M |
| alyeska investment group, l.p. | 850,000 | $5.8M |
| vanguard portfolio management llc | 742,571 | $5.0M |
Showing top 10 of 189 institutional holders of CorMedix Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 21.0%
- Days to cover
- 16.0
- Shares short
- 16,222,947
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CRMD short interestGovernance
Frequently asked questions
What is the AI investment thesis for CorMedix Inc.?
CorMedix Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for the prevention of catheter-related bloodstream infections, with its lead product DefenCath (taurolidine and heparin) approved and launched in the U.S. dialysis market.
What is CorMedix Inc.'s lead drug candidate?
CorMedix Inc.'s most advanced tracked candidate is DefenCath (Phase 4) for reduction of central line associated bloodstream infection (CLABSI) in adult patients receiving total parental nutrition (TPN).
What is CorMedix Inc.'s next catalyst?
CorMedix Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3, Prospective, Multicenter, Double-Blind, Randomized, Controlled, Adaptive Study To Demonst" — expected January 1, 2028.
Who is the CEO of CorMedix Inc.?
Mr. Joseph Todisco MBA is the chief executive officer of CorMedix Inc. (CRMD).
Where is CorMedix Inc. headquartered?
CorMedix Inc. (CRMD) is headquartered in Parsippany, NJ, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.